Contrasting STAAR Surgical (STAA) & The Cooper Companies (COO)

STAAR Surgical (NASDAQ: STAA) and The Cooper Companies (NYSE:COO) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.

Earnings and Valuation

This table compares STAAR Surgical and The Cooper Companies’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
STAAR Surgical $90.61 million 7.69 -$2.13 million $0.01 1,675.00
The Cooper Companies $2.14 billion 5.16 $372.90 million $9.70 23.21

The Cooper Companies has higher revenue and earnings than STAAR Surgical. The Cooper Companies is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

79.0% of STAAR Surgical shares are held by institutional investors. Comparatively, 98.5% of The Cooper Companies shares are held by institutional investors. 5.6% of STAAR Surgical shares are held by company insiders. Comparatively, 1.6% of The Cooper Companies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares STAAR Surgical and The Cooper Companies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
STAAR Surgical -2.36% -2.28% -1.34%
The Cooper Companies 7.83% 16.90% 10.11%

Analyst Ratings

This is a summary of recent ratings and price targets for STAAR Surgical and The Cooper Companies, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
STAAR Surgical 0 0 2 0 3.00
The Cooper Companies 0 7 6 0 2.46

STAAR Surgical presently has a consensus target price of $20.50, suggesting a potential upside of 22.39%. The Cooper Companies has a consensus target price of $264.90, suggesting a potential upside of 17.67%. Given STAAR Surgical’s stronger consensus rating and higher possible upside, research analysts plainly believe STAAR Surgical is more favorable than The Cooper Companies.

Risk and Volatility

STAAR Surgical has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, The Cooper Companies has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.

Dividends

The Cooper Companies pays an annual dividend of $0.06 per share and has a dividend yield of 0.0%. STAAR Surgical does not pay a dividend. The Cooper Companies pays out 0.6% of its earnings in the form of a dividend.

Summary

The Cooper Companies beats STAAR Surgical on 9 of the 16 factors compared between the two stocks.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers minimally invasive intraocular lenses (IOLs), including foldable IOLs for use in minimally invasive cataract surgical procedures; aspheric IOLs that produce a clearer image than traditional spherical lenses; and nanoFLEX IOL, a single piece collamer aspheric optic, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision centers, surgical centers, hospitals, government facilities, and distributors primarily under the STAAR, EVO Visian ICL, Evolution in Visual Freedom, Visian, Collamer, CentraFLOW, AquaPORT, nanoFLEX, nanoPOINT, and Afinity trademarks. The company sells products directly through its sales representatives in the United States, Japan, Spain, Germany, Canada, the United Kingdom, and Singapore, as well as through independent distributors in approximately 75 countries. STAAR Surgical Company was founded in 1982 and is headquartered in Monrovia, California.

About The Cooper Companies

The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia. It also provides range of products and services focusing on women's health, including medical devices, fertility, genomics, and diagnostics and contraception for hospitals and surgical centers, obstetricians' and gynecologists' (ob/gyns) medical offices, and fertility clinics. In addition, the company offers carrier screening, preimplantation genetic screening, and preimplantation genetic diagnosis used in IVF process; IVF medical devices, systems, and equipment; and PARAGARD, a non-hormonal, copper intrauterine device for birth control. Further, The Cooper Companies, Inc. offers its products under Biofinity, clarity 1day, MyDay, and Proclear 1 Day brand name. The company markets its products through a network of field sales representatives, independent agents, and distributors. The Cooper Companies, Inc. was founded in 1980 and is headquartered in Pleasanton, California.

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply